UTMD Valuation
Utah Medical Products Inc
$
53.630
- Overview
- Forecast
- Valuation
UTMD Relative Valuation
UTMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UTMD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for UTMD's competitors is 1.69, providing a benchmark for relative valuation. Utah Medical Products Inc Corp (UTMD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -14.37%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
CIO
City Office REIT Inc
4.780
USD
-1.44%
AZ
A2Z Smart Technologies Corp
8.970
USD
-1.70%
JRVR
James River Group Holdings Ltd
5.345
USD
-0.83%
ESCA
Escalade Inc
15.070
USD
+0.60%
SOPH
Sophia Genetics SA
2.880
USD
0.00%
APPS
Digital Turbine Inc
4.375
USD
-5.51%
HWBK
Hawthorn Bancshares Inc
31.240
USD
+0.32%
AEYE
AudioEye Inc
12.730
USD
-0.62%
GROY
Gold Royalty Corp
1.780
USD
+4.09%
SJT
San Juan Basin Royalty Trust
6.850
USD
+6.53%
FAQ
Is Utah Medical Products Inc (UTMD) currently overvalued or undervalued?
Utah Medical Products Inc (UTMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Utah Medical Products Inc (UTMD) is between to according to relative valuation methord.
What is Utah Medical Products Inc (UTMD) fair value?
How does UTMD's valuation metrics compare to the industry average?
What is the current P/B ratio for Utah Medical Products Inc (UTMD) as of May 21 2025?
What is the current FCF Yield for Utah Medical Products Inc (UTMD) as of May 21 2025?
What is the current Forward P/E ratio for Utah Medical Products Inc (UTMD) as of May 21 2025?